Cargando…

Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study

BACKGROUND: Hepatocholangiocarcinoma (cHCC-ICC) is a rare liver tumour for which no data on chemosensitivity exist. The aims of this multicentre study were to evaluate overall survival (OS), progression-free survival (PFS), and prognostic factors in cHCC-ICC treated by gemcitabine plus platinum as f...

Descripción completa

Detalles Bibliográficos
Autores principales: Salimon, Maëva, Prieux-Klotz, Caroline, Tougeron, David, Hautefeuille, Vincent, Caulet, Morgane, Gournay, Jérôme, Matysiak-Budnik, Tamara, Bennouna, Jaafar, Tiako Meyo, Manuela, Lecomte, Thierry, Zaanan, Aziz, Touchefeu, Yann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808029/
https://www.ncbi.nlm.nih.gov/pubmed/29169182
http://dx.doi.org/10.1038/bjc.2017.413
_version_ 1783299384302108672
author Salimon, Maëva
Prieux-Klotz, Caroline
Tougeron, David
Hautefeuille, Vincent
Caulet, Morgane
Gournay, Jérôme
Matysiak-Budnik, Tamara
Bennouna, Jaafar
Tiako Meyo, Manuela
Lecomte, Thierry
Zaanan, Aziz
Touchefeu, Yann
author_facet Salimon, Maëva
Prieux-Klotz, Caroline
Tougeron, David
Hautefeuille, Vincent
Caulet, Morgane
Gournay, Jérôme
Matysiak-Budnik, Tamara
Bennouna, Jaafar
Tiako Meyo, Manuela
Lecomte, Thierry
Zaanan, Aziz
Touchefeu, Yann
author_sort Salimon, Maëva
collection PubMed
description BACKGROUND: Hepatocholangiocarcinoma (cHCC-ICC) is a rare liver tumour for which no data on chemosensitivity exist. The aims of this multicentre study were to evaluate overall survival (OS), progression-free survival (PFS), and prognostic factors in cHCC-ICC treated by gemcitabine plus platinum as first-line. METHODS: Unresectable cHCC-ICC treated by gemcitabine plus platinum-based chemotherapy between 2008 and 2017 were retrospectively analysed. Diagnosis was based on histology or, in case of ICC or HCC histology, on discordant computerised tomography scan enhancement patterns associated with discordant serum tumour marker elevation suggesting the alternative tumour. OS and PFS were evaluated by Kaplan–Meier method and prognostic factors by Log-rank test and Cox model. RESULTS: Among 30 patients included, cHCC-ICC was histologically proven in 22 (73.3%). 18 (60%) received gemcitabine plus oxaliplatin (GEMOX), 9 (30%) GEMOX plus bevacizumab, and 3 (10%) gemcitabine plus cisplatin. RECIST criteria were reported in 28 patients: 8 (28.6%) showed partial response, 14 (50%) stable disease, and 6 (21.4%) tumour progression at first evaluation. Median PFS and OS were 9.0 and 16.2 months, respectively. Serum bilirubin ⩾30 μmol l(−1) (P=0.001) and positive serology for HBV and/or HCV (P=0.014) were independent poor prognostic factors for OS. CONCLUSIONS: Gemcitabine plus platinum-based chemotherapy is effective as first-line for advanced cHCC-ICC.
format Online
Article
Text
id pubmed-5808029
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-58080292019-02-06 Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study Salimon, Maëva Prieux-Klotz, Caroline Tougeron, David Hautefeuille, Vincent Caulet, Morgane Gournay, Jérôme Matysiak-Budnik, Tamara Bennouna, Jaafar Tiako Meyo, Manuela Lecomte, Thierry Zaanan, Aziz Touchefeu, Yann Br J Cancer Clinical Study BACKGROUND: Hepatocholangiocarcinoma (cHCC-ICC) is a rare liver tumour for which no data on chemosensitivity exist. The aims of this multicentre study were to evaluate overall survival (OS), progression-free survival (PFS), and prognostic factors in cHCC-ICC treated by gemcitabine plus platinum as first-line. METHODS: Unresectable cHCC-ICC treated by gemcitabine plus platinum-based chemotherapy between 2008 and 2017 were retrospectively analysed. Diagnosis was based on histology or, in case of ICC or HCC histology, on discordant computerised tomography scan enhancement patterns associated with discordant serum tumour marker elevation suggesting the alternative tumour. OS and PFS were evaluated by Kaplan–Meier method and prognostic factors by Log-rank test and Cox model. RESULTS: Among 30 patients included, cHCC-ICC was histologically proven in 22 (73.3%). 18 (60%) received gemcitabine plus oxaliplatin (GEMOX), 9 (30%) GEMOX plus bevacizumab, and 3 (10%) gemcitabine plus cisplatin. RECIST criteria were reported in 28 patients: 8 (28.6%) showed partial response, 14 (50%) stable disease, and 6 (21.4%) tumour progression at first evaluation. Median PFS and OS were 9.0 and 16.2 months, respectively. Serum bilirubin ⩾30 μmol l(−1) (P=0.001) and positive serology for HBV and/or HCV (P=0.014) were independent poor prognostic factors for OS. CONCLUSIONS: Gemcitabine plus platinum-based chemotherapy is effective as first-line for advanced cHCC-ICC. Nature Publishing Group 2018-02-06 2017-11-23 /pmc/articles/PMC5808029/ /pubmed/29169182 http://dx.doi.org/10.1038/bjc.2017.413 Text en Copyright © 2018 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/4.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
spellingShingle Clinical Study
Salimon, Maëva
Prieux-Klotz, Caroline
Tougeron, David
Hautefeuille, Vincent
Caulet, Morgane
Gournay, Jérôme
Matysiak-Budnik, Tamara
Bennouna, Jaafar
Tiako Meyo, Manuela
Lecomte, Thierry
Zaanan, Aziz
Touchefeu, Yann
Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study
title Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study
title_full Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study
title_fullStr Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study
title_full_unstemmed Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study
title_short Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study
title_sort gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an ageo french multicentre retrospective study
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808029/
https://www.ncbi.nlm.nih.gov/pubmed/29169182
http://dx.doi.org/10.1038/bjc.2017.413
work_keys_str_mv AT salimonmaeva gemcitabineplusplatinumbasedchemotherapyforfirstlinetreatmentofhepatocholangiocarcinomaanageofrenchmulticentreretrospectivestudy
AT prieuxklotzcaroline gemcitabineplusplatinumbasedchemotherapyforfirstlinetreatmentofhepatocholangiocarcinomaanageofrenchmulticentreretrospectivestudy
AT tougerondavid gemcitabineplusplatinumbasedchemotherapyforfirstlinetreatmentofhepatocholangiocarcinomaanageofrenchmulticentreretrospectivestudy
AT hautefeuillevincent gemcitabineplusplatinumbasedchemotherapyforfirstlinetreatmentofhepatocholangiocarcinomaanageofrenchmulticentreretrospectivestudy
AT cauletmorgane gemcitabineplusplatinumbasedchemotherapyforfirstlinetreatmentofhepatocholangiocarcinomaanageofrenchmulticentreretrospectivestudy
AT gournayjerome gemcitabineplusplatinumbasedchemotherapyforfirstlinetreatmentofhepatocholangiocarcinomaanageofrenchmulticentreretrospectivestudy
AT matysiakbudniktamara gemcitabineplusplatinumbasedchemotherapyforfirstlinetreatmentofhepatocholangiocarcinomaanageofrenchmulticentreretrospectivestudy
AT bennounajaafar gemcitabineplusplatinumbasedchemotherapyforfirstlinetreatmentofhepatocholangiocarcinomaanageofrenchmulticentreretrospectivestudy
AT tiakomeyomanuela gemcitabineplusplatinumbasedchemotherapyforfirstlinetreatmentofhepatocholangiocarcinomaanageofrenchmulticentreretrospectivestudy
AT lecomtethierry gemcitabineplusplatinumbasedchemotherapyforfirstlinetreatmentofhepatocholangiocarcinomaanageofrenchmulticentreretrospectivestudy
AT zaananaziz gemcitabineplusplatinumbasedchemotherapyforfirstlinetreatmentofhepatocholangiocarcinomaanageofrenchmulticentreretrospectivestudy
AT touchefeuyann gemcitabineplusplatinumbasedchemotherapyforfirstlinetreatmentofhepatocholangiocarcinomaanageofrenchmulticentreretrospectivestudy